ReviewThe Yale journal of biology and medicine
Pathogenesis of ECL cell tumors in humans.
Review in The Yale journal of biology and medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 75 citations in OpenAlex.
- The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease.Internal medicine (Tokyo, Japan) · 2022Article
- Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach.Clinical journal of gastroenterology · 2020Review
- Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.Endocrine reviews · 2019Review
- Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may targetWorld journal of gastroenterology · 2018Article
- Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy.Clinical journal of gastroenterology · 2017Article
- Hypergastrinemia.Gastroenterology report · 2015Review
- CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas.European radiology · 2015Observational
- Gastric cancer in patients with type I gastric carcinoids.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2015Article
- Somatostatin analogs for gastric carcinoids: For many, but not all.World journal of gastroenterology · 2015Review
- Urticaria as initial finding of a patient with carcinoid tumor.The World Allergy Organization journal · 2015Article
- Neuroendocrine pathology of the stomach: the Parma contribution.Endocrine pathology · 2014Review
- Neuroendocrine carcinoma of the stomach-a case report.Journal of clinical and diagnostic research : JCDR · 2014Article
- 79-year-old woman with forgetfulness.Mayo Clinic proceedings · 2012Article
- Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal.World journal of gastroenterology · 2012Review
- The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.Protein and peptide letters · 2009Review
- Classification of tumours.Journal of experimental & clinical cancer research : CR · 2008Article
- Hereditary neuroendocrine tumors of the gastroenteropancreatic system.Virchows Archiv : an international journal of pathology · 2007Review
- Treatment of gastric carcinoids.Current treatment options in gastroenterology · 2007Article
- Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.Current topics in medicinal chemistry · 2007Review
- Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors.Endocrine pathology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In ECL cell tumors developed in the setting of hypergastrinemic conditions (ECL cell carcinoids type 1 and 2), hypergastrinemia is the dominant agent acting as a promoter in all steps (hyperplasia-dysplasia-neoplasia) of the tumorigenic sequence. In contrast, it apparently lacks transforming properties as shown by the absence of ECL cell carcinoids in patients exposed to hypergastrinemia alone, i.e., those with sporadic Zollinger-Ellison syndrome. The potential transforming factors include: the allelic loss of the MEN-1 suppressor gene in the genetically predisposed MEN-1 patients, an alteration that may induce ECL cell tumors even in the absence of hypergastrinemia; the still unknown factor(s) associated with atrophic corporal gastritis; agents whose role in the induction of human ECL cell tumors is still unclarified, such as basic Fibroblast Growth Factor, human Chorionic Gonadotropin-alpha and Transforming Growth Factor-alpha; and agents having a favoring role on the ECL exposure to mitogens such as BCL-2. No information is currently available on the pathogenesis of gastrin-independent, sporadic ECL cell carcinoids (type 3) or of gastric neuroendocrine carcinomas.
Indexed as
Identifiers
10461358PMC2578995W203119495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.